Inventiva announced the appointment of Renée Aguiar-Lucander to its Board of Directors. This appointment was approved by shareholders at the Company’s recent Annual General Meeting.
Ms. Aguiar-Lucander's addition to the board is expected to bring valuable experience and insights to Inventiva's governance. Her expertise will support the company as it continues to advance its lead drug candidate, lanifibranor, through clinical development.
This change in the Board of Directors is part of Inventiva's ongoing efforts to strengthen its leadership and strategic oversight as it approaches key milestones in the MASH therapeutic space.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.